At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Mar 15, 2026 at 20:00 ET
Multiple C-suite executives at Bicara Therapeutics (BCAX) exercised stock options and sold shares in the open market over a 7-day period, generating over $483,000 in total proceeds from sales. The transactions were primarily driven by option exercises followed by corresponding sales to cover taxes and realize gains, with no open-market purchases observed.
- CEO Mazumdar Claire and CFO Hyep Ivan exercised derivative securities (stock options) and sold the resulting shares in open-market transactions.
- Total open-market sales amounted to $483,168.03 across 30,200 shares sold at prices between $18.52 and $18.95.
- All transactions involving cash proceeds were sales; no open-market purchases were made.
- Non-cash transactions (codes M and A) totaled $81,611.52 in value, related to option exercises at $3.7898 strike price.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access